



COVADIS

Coronary Vasomotor Disorders International Study Group

8th Annual COVADIS Summit

Wednesday 9th September 2020

First Virtual COVADIS Summit

Los Angeles	6.00am
New York	9.00am
London	2.00pm
Rome	3.00pm
Tokyo	10.00pm
Adelaide	10.30pm



COVADIS

Coronary Vasomotor Disorders International Study Group

2020 Virtual Summit Program

Investigating Patients with Suspected Stable Angina: Beyond ISCHEMIA

TIME (EDT)	TOPIC	CHAIR
9.00am	Welcome, Overview of COVADIS and virtual summit goals	C. Noel Bairey Merz, US
9:10am	Introductions of the invited ISCHEMIA Trial Speakers	John Beltrame, AU
	Judith Hochman, US (confirmed) – 5 min remarks	
	Gregg Stone, US (confirmed) – 5 min remarks	
9:20-10:30am	Summit Panel Discussion of Panel Questions Invited Panel Members: William Boden, US (confirmed) Patrick O’Gara, US (confirmed) COVADIS Steering Committee	C. Noel Bairey Merz, US & John Beltrame, AU
10.30am	Close	John Beltrame, AU



COVADIS

Coronary Vasomotor Disorders International Study Group

Mission Statements



<https://covadis.online/>



COVADIS

Coronary Vasomotor Disorders International Study Group

2020 Virtual Summit Program

Investigating Patients with Suspected Stable Angina: Beyond ISCHEMIA

TIME (EDT)	TOPIC	CHAIR
9.00am	Welcome, Overview of COVADIS and virtual summit goals	C. Noel Bairey Merz, US
9:10am	Introductions of the invited ISCHEMIA Trial Speakers	John Beltrame, AU
	Judith Hochman, US (confirmed) – 5 min remarks	
	Gregg Stone, US (confirmed) – 5 min remarks	
9:20-10:30am	Summit Panel Discussion of Panel Questions Invited Panel Members: William Boden, US (confirmed) Patrick O’Gara, US (confirmed) COVADIS Steering Committee	C. Noel Bairey Merz, US & John Beltrame, AU
10.30am	Close	John Beltrame, AU



COVADIS

Coronary Vasomotor Disorders International Study Group

Prof Judith Hochman

Department of Medicine, Grossman School of Medicine, NYU Langone

- Harold Snyder Family Professor of Cardiology
- Senior Associate Dean for Clinical Sciences
- Co-Director, Clinical and Translational Science Institute
- Director, Cardiovascular Clinical Research Center

Leon H Charney Division of Cardiology, Department of Medicine, NYU Langone Health

- Associate Director

NYU Langone, New York, USA

ISCHEMIA Trial Study Chair

Investigating Patients with Suspected Stable Angina: Beyond ISCHEMIA



COVADIS

Coronary Vasomotor Disorders International Study Group

Prof Gregg Stone

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine

- Professor of Medicine
- Professor of Population Health Sciences and Policy

Mount Sinai Heart Health System

- Director of Academic Affairs for Mount Sinai Heart

Mount Sinai, New York, USA

ISCHEMIA Trial Steering Committee

Investigating Patients with Suspected Stable Angina: Beyond ISCHEMIA



COVADIS

Coronary Vasomotor Disorders International Study Group

2020 Virtual Summit Program

Investigating Patients with Suspected Stable Angina: Beyond ISCHEMIA

TIME (EDT)	TOPIC	CHAIR
9.00am	Welcome, Overview of COVADIS and virtual summit goals	C. Noel Bairey Merz, US
9:10am	Introductions of the invited ISCHEMIA Trial Speakers	John Beltrame, AU
	Judith Hochman, US (confirmed) – 5 min remarks	
	Gregg Stone, US (confirmed) – 5 min remarks	
9:20-10:30am	Summit Panel Discussion of Panel Questions	C. Noel Bairey Merz, US & John Beltrame, AU
	Invited Panel Members: William Boden, US (confirmed) Patrick O’Gara, US (confirmed) COVADIS Steering Committee	
10.30am	Close	John Beltrame, AU



COVADIS

Coronary Vasomotor Disorders International Study Group

Discussion Questions

Proposed Questions for 2020 COVADIS Summit Panel Discussion - Investigating Patients with Suspected Stable Angina: Beyond ISCHEMIA – moderated by COVADIS Steering Committee members

1. What are the barriers to the understanding/acceptance of functional mechanisms, such as coronary vasomotor disorders including, coronary microvascular dysfunction (CMD) and coronary vasospasm, as a cause of myocardial ischemia? **Filippo Crea**
2. What are reasons for the reluctance by the interventional community and traditional cardiologists to accept microvascular angina (MVA) as a clinical entity in its own right? **Juan Carlos Kaski**
3. Cath lab time spent assessing functional mechanisms is not time wasted, or is it? **Peter Ong**
4. Should interventional cardiologists take advantage of the current reduction in intervention numbers to incorporate functional testing to their routine activity? **Udo Sechem**
5. Lessons from ISCHEMIA, if any. Should there be any changes in the interventional approach after ISCHEMIA, ORBITA, and CorMicA? **Colin Berry**
6. What next steps might contribute to coronary microvascular dysfunction (CMD) and MVA to become accepted concepts in the interventional cardiologist's world? **Hiro Shimokawa**
7. Specifically, what would be useful to embrace CMD and MVA as etiological for persistent or recurrent angina post successful PCI? **Paolo Camici**
8. What research agenda would be useful to expand understanding, diagnosis and treatment of coronary vasomotor disorders in ischemic heart disease? **Carl Pepine**